RESUMEN
BACKGROUND: Multiple Sclerosis (MS) is an immune-mediated demyelinating disease mainly affecting the Central Nervous System (CNS). 80% of MS patients present the Relapsing-Remitting form (RRMS). Pleiotrophin (PTN), a cytokine previously associated with other autoimmune and neurological diseases, could play a role in the pathophysiology of RRMS due to its neuro and immunomodulatory effect. However, PTN has never been explored in RRMS patients. AIM OF THE STUDY: To determine PTN serum levels in patients with RRMS, treated with Glatiramer acetate (GA) or Interferon-beta (IFN-ß), as well as in non-treated patients and healthy controls as a first attempt to explore PTN in RRMS. METHODS: PTN serum levels were quantified by ELISA in 57 patients and 18 controls. RESULTS: We demonstrated that PTN serum levels are significantly higher in RRMS patients. In IFN-ß treated patients alone, PTN correlated positively with time of disease evolution and time of IFN-ß use and correlated negatively with the MS severity score (MSSS). When comparing groups according to weight status, we observed that PTN is statistically increased in overweight female patients and that weight does not affect male patients. The Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve analysis was higher for males compared to females. CONCLUSION: PTN serum level is higher in RRMS patients and that is associated with sex, BMI and IFN-ß treatment. Therefore, we propose that PTN could be playing a role in MS. Further studies must be performed to identify the exact role of PTN in this pathology.